Background
==========

Worldwide, infertility affects one-sixth of couples and male infertility comprises half of infertility cases, resulting in significant costs to healthcare services and emotional costs. The main cause of male infertility is spermatogenic failure including azoospermia and oligozoospermia. Most male infertility cases present as nonobstructive azoospermia (NOA), which occurs in approximately 1% of adult men. Currently, studies have shown that genetic factors may be the main cause of NOA \[[@b1-medscimonit-25-5801],[@b2-medscimonit-25-5801]\]. In the past decades, genetic tests for male infertility have been developed and are used routinely, including karyotyping for Klinefelter syndrome and Y chromosome microdeletion testing. These tests are of significant benefit to patients. However, known genetic causes account for less than one-third of all cases of male infertility, resulting in most cases of male infertility being classified as idiopathic \[[@b3-medscimonit-25-5801]\].

Currently, genome-wide association studies (GWAS) have successfully identified affected *loci* of several complex diseases. Single nucleotide variants (SNVs) and other common structural variants are reported to be associated with NOA, but study findings have not been replicated in separate independent populations \[[@b4-medscimonit-25-5801]--[@b7-medscimonit-25-5801]\]. Also, GWAS have failed to identify a reasonable proportion of the heritability of complex traits \[[@b8-medscimonit-25-5801]\]. One explanation for overlooking heritability maybe the loss of rare and low-frequency variants, which are not well captured by current methods \[[@b9-medscimonit-25-5801]\].

Previous studies have shown that targeted gene capture sequencing technology can be used to detect rare variants with high throughput and speed, but low cost \[[@b3-medscimonit-25-5801]\]. Therefore, this study aimed to screen common and low-frequency variants of NOA-associated genes from the Han population of northeast China and to construct a database for NOA-associated SNVs. Targeted NOA-associated genes were collected from databases and prior gene resequencing studies including GWAS data. Exonic regions of genes were sequenced with significant roles in NOA populations to identify common variants and to select rare, low-frequency variants that played a significant role, using Baylor's pipeline to identify statistically valid SNVs \[[@b10-medscimonit-25-5801]\].

Material and Methods
====================

Patients
--------

This study was approved by the Ethics Committee of the First Hospital of Jilin University. All study participants provided written informed consent. All cases were first identified through comprehensive andrological testing, including medical history and physical examination. Basic demographic and clinical information including patient age were collected by professional investigators using clinical questionnaires. Eligibility criteria for participants included men aged between 20--40 years at the time of hospital admission, and both the male and his mother were required to have been born and were living in northeast China.

Semen analysis was performed using the standards provided by 5^th^ edition of the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen \[[@b11-medscimonit-25-5801]\]. Diagnosis of azoospermia was based on semen analysis as the absence of sperm in the ejaculate, serum hormone levels, and the findings from physical examination. Patients with any known cause of infertility were excluded, including obstructive azoospermia, varicocele, cryptorchidism, hypogonadotropic hypogonadism, karyotype abnormalities, and deletion of azoospermia factor (AZF). Deletions in AZF a, b, and c were analyzed according to the European Academy of Andrology and the European Molecular Genetics Quality Network best practice guidelines \[[@b12-medscimonit-25-5801]\].

There were 34 patients with NOA with a mean age of 29.06±4.49 years who were diagnosed in the Center for Reproductive Medicine of the First Hospital of Jilin University from September 2013 to December 2014, and they were included in the NOA group. A further 40 sperm donors were identified as the control group, with a mean age of 25.08±5.75 years, who attended the Sperm Bank of Jilin Province from September 2013 to December 2014.

Targeted next-generation sequencing
-----------------------------------

There were 466 targeted NOA-associated genes identified from animal models or previous publications and by referring to the following databases: Online Mendelian Inheritance in Man (OMIM), GENCODE, the NCI Reference Sequence Database (RefSeq), Vega Genome Browser, and PubMed. A NimbleGen custom capture array (Roche, Basel, Switzerland) was designed to capture all exons, splice sites, and adjacent intron sequences of these genes.

Genomic DNA was extracted from peripheral blood samples using a blood DNA kit (TIANGEN Biotech, Beijing, China). Targeted sequence enrichment was performed using the GenCap custom enrichment kit (MyGenostics, Beijing, China). For library preparation, end-repair, acetylation, and adapter ligation were performed following standard protocols, with sequencing performed using an Illumina HiSeq2000 Analyzer (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. Image analysis, error estimation, and base calling were performed. Data filtering and analysis were performed, as previously described \[[@b13-medscimonit-25-5801]\].

Construction of the single nucleotide variant SNV database
----------------------------------------------------------

The flowchart of the case-control study is shown in [Figure 1](#f1-medscimonit-25-5801){ref-type="fig"}. Construction of the SNV database was performed by summarizing non-negatively associated SNVs showing a statistical difference between the NOA and control groups, then selecting SNVs by Baylor's pipeline ([Figure 2](#f2-medscimonit-25-5801){ref-type="fig"}) and SNVs with a minor allele frequency (MAF) of 0 in the control group. The dbSNP public-domain archive for human SNVs and the Human Gene Mutation Database (HGMD) were interrogated to construct the SNV database.

Statistical analysis
--------------------

All statistical analysis was performed using SPSS version 19.0 software (IBM Corporation, Armonk, NY, USA). A p-value \<0.05 was accepted as a statistically significant difference. Further, t-tests were used to identify the differences in continuous variables, such as age and hormones. Allele frequencies were compared between cases of NOA and controls with normozoospermia using the chi-squared (χ^2^) test. When the theoretical allele frequency \<1, allele frequencies were compared between cases and controls by Fisher's exact test. The Hardy-Weinberg equilibrium test was performed for each SNP using the internet calculation program (*<https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>*). Estimated infertile risks with odds ratios (OR) and 95% confidence interval (95% CI) were calculated by the binary logistic regression method corrected with age as the covariant.

Results
=======

Clinical information
--------------------

Significant differences were found in average age, body mass index (BMI), sperm concentration, serum follicle-stimulating hormone (FSH) levels, serum luteinizing hormone (LH) levels, serum prolactin (PL) levels, and serum testosterone levels between the nonobstructive azoospermia (NOA) group and the control group (p \<0.05). No statistically significant differences were found in the rate of varicocele, semen volume, and serum estradiol (E2) levels between the two groups (p\>0.05) ([Table 1](#t1-medscimonit-25-5801){ref-type="table"}).

Quality threshold
-----------------

A large number of high-quality outcomes was produced by targeted resequencing. There was an align rate of 100% in \>95% (99.45--98.13%). Coverage rate with at least 20×sequencing depth was 99.9--92% and most were \>95% and only one case was 92%. The 100% duplication rate was \<20%.

Screening of potential genetic variants
---------------------------------------

In total, 178,966 variants were detected by sequencing 74 cases. There were 65% variants in intronic regions, 24% within exonic regions, 10% in regulatory regions, and \<1% located in non-regulatory intergenic regions ([Table 2](#t2-medscimonit-25-5801){ref-type="table"}).

The 178,966 variants could be divided into two types, the single nucleotide variants (SNVs) and insertions and deletions (Indels) ([Table 3](#t3-medscimonit-25-5801){ref-type="table"}). Non-synonymous, synonymous, stop-gain, stop-loss, splicing, and unknown types were included as SNVs. Frameshift, non-frameshift, stop-loss, and unknown types were included as Indels. The rate of unknown types showed a significant difference between the NOA group and the control group (p\<0.001). From these 178,966 variants, 2,391 exonic SNVs with at least 20×sequencing depth were selected for the case-control study (Indel variants were not analyzed in this study).

Minor allele frequencies (MAFs) of SNVs compared between groups
---------------------------------------------------------------

Of the 2,391 SNVs, minor allele frequencies (MAFs) were compared between the NOA group and control group. The Hardy-Weinberg equilibrium (HWE) was calculated in the NOA and control groups. Subsequently, 65 SNVs with significant differences in MAFs were found between groups (p\<0.05) ([Table 4](#t4-medscimonit-25-5801){ref-type="table"}). Of these SNVs, the distribution of 38 SNVs was in agreement with the HWE (p\>0.05).

Association between selected variants and NOA
---------------------------------------------

Association studies between these 38 SNVs and NOA were performed and corrected with age as the covariant. We found that 18 SNVs showed significant correlations with NOA (p\<0.05) ([Table 5](#t5-medscimonit-25-5801){ref-type="table"}). Five genetic variants showed positive correlations with NOA and included: *MTRR* c.537T\>C (rs161870), odds ratios (OR), 3.686, 95% confidence interval (CI), 1.228--11.066; *MTRR*, c.1049A\>G (rs162036), OR, 3.686, 95% CI, 1.228--11.066; *PIWIL1*, c.1580G\>A (rs1106042), OR, 4.737, 95% CI, 1.314--17.072; *TAF4B*, c.1815T\>C (rs1677016), OR, 3.599, 95% CI, 1.255--10.327; and *SOX10* c.927T\>C (rs139884), OR, 3.192, 95% CI, 1.220--8.353. Also, 52 NOA non-negatively associated SNVs and 39 SNVs were identified by Baylor's pipeline and selected for the SNV database.

The other 13 genetic variants showed negative correlations with NOA and included *KIF2C*, c.531A\>T (rs3795713), OR, 0.291; *KIF2C*, c.1345A\>C (rs4342887), OR, 0.291; *KIF2C*, c.1500G\>A (rs1140279), OR, 0.291; *MAEL*, c.12T\>C (rs2296837), OR, 0.316; *MAEL*, c.121T\>G (rs11578336), OR, 0.345; *HLA--DRB1*, c.227T\>A (rs17884945), OR, 0.254; *HLA--DPB1*, c.292A\>G \[rs1042140, OR: 0.431\], *HLA--DPB1*, c.313A\>G (rs1042151), OR, 0.198; *HLA--DPB1*, c.315G\>A (rs1042153), OR, 0.181; *ACE*, c.81C\>T (rs4316), OR, 0.351; *ACE*, c.471A\>G (rs4331), OR, 0.351; *ACE*, c.606G\>A (rs4343), OR, 0.351; and *ACE*, c.1665T\>C (rs4362), OR, 0.283. None of the 18 SNVs were registered as pathogenic variants associated with NOA in the Human Gene Mutation Database (HGMD).

Selection of rare and low-frequency variants by Baylor's pipeline
-----------------------------------------------------------------

SNVs without significant differences in MAF between the NOA group and control group were further selected using a Baylor's pipeline approach. Finally, there were 73 SNVs selected from 62,376 candidate SNVs by Baylor's pipeline. These 73 SNVs underwent further selection based on MAF in the control group. We found 42 SNVs with a MAF of 0 in the control group, which were ultimately selected. All 42 SNVs were distributed among 39 SNV sites within 34 genes ([Table 6](#t6-medscimonit-25-5801){ref-type="table"}).

SNV database
------------

The SNV database was constructed using 52 NOA non-negatively associated SNVs and 39 SNVs. We found that 5.45% (5/91) of the library was positively associated with NOA. Furthermore, 21.98% (20/91) showed significant differences in MAF between both groups, but with no significant deviation from the HWE and no significant association with NOA. Also, 29.67% (27/91) of the library showed significant differences in MAF between the groups and significant deviations from HWE. Additionally, 42.86% (39/91) were single-nucleotide mutations. Only 1.1% (1/91) of the library could be retrieved from the Human Gene Mutation Database (HGMD). Meanwhile, 87.91% (80/91) of the library could be retrieved only from the dbSNP public-domain archive for human SNVs, while 6.59% (6/91) could be retrieved from both the HGMD and dbSNP databases. In contrast, 4.4% (4/91) of the library could be retrieved from neither the HGMD nor dbSNP databases. Finally, 62.64% (57/91) of the library were nonsynonymous variations and 37.36% (34/91) were synonymous variations.

Discussion
==========

Clinically, nonobstructive azoospermia (NOA) is a common cause of male infertility, yet the factors involved in its pathogenesis remain unknown. It has previously been shown that idiopathic nonobstructive azoospermia (NOA) may be associated with genetic abnormalities \[[@b14-medscimonit-25-5801]\]. Genetic association studies have identified several susceptibility single nucleotide variants (SNVs) for NOA. However, Park et al. \[[@b15-medscimonit-25-5801]\] noted that fine-mapping studies have so far failed to find common variants with larger effect sizes than their tagging SNVs and these authors proposed extending their method to predict the yield of rarer genome-wide variants.

Although whole-genome sequencing technology can be used to decipher gene variants, the high cost of this method and difficulties in analysis still prevent its wider application. Therefore, targeted sequencing of genomic regions of interest is an available approach. Some reports have used targeted gene capture sequencing technology in research and diagnosis for several complex disorders and common diseases. A previous study demonstrated that this technology can be used for the detection of rare gene variants with high fidelity, throughput, and speed, and at low cost \[[@b13-medscimonit-25-5801]\]. Currently, there is no commercial diagnostic panel for NOA. Therefore, in this study we collected 466 targeted NOA-associated genes as a panel. After sequencing these genes, 65 SNVs were identified with significant differences in minor allele frequencies (MAFs) between groups (p \<0.05). Of these SNVs, five showed positive correlations with NOA in the Chinese Han population, specifically, *MTRR*, c.537T\>C (rs161870), *MTRR*, c.1049A\>G (rs162036), *PIWIL1*, c.1580G\>A (rs1106042), *TAF4B*, c.1815T\>C (rs1677016), and *SOX10*, c.927T\>C (rs139884) ([Table 5](#t5-medscimonit-25-5801){ref-type="table"}).

*MTRR* (MIM: 602568) is also known as methionine synthase reductase. This gene encodes a member of the ferredoxin-NADP(+) reductase family of electron transferases. *MTRR* has previously been reported as a potential candidate for male infertility or reduced spermatogenesis \[[@b16-medscimonit-25-5801]\]. In the present study, the *MTRR* variant, c.537T\>C (rs161870), was a synonymous mutation, with previous reports of this genetic variant being associated with disease. The *MTRR* variant, c.1049A\>G (rs162036), is a non-synonymous mutation that can change amino acid 350 from lysine to arginine, and this genetic variant has been previously associated with gastrointestinal stromal tumor (GIST) \[[@b17-medscimonit-25-5801]\].

The *PIWIL1* gene encodes a member of the PIWI subfamily of Argonaute proteins, which have a role as intrinsic regulators of self-renewal in germline and hematopoietic stem cells. Genetic polymorphisms in *PIWI* genes have been reported to increase the risk of oligozoospermia \[[@b18-medscimonit-25-5801]\]. A stem cell expression signature associated with *PIWIL1* expression has also been reported \[[@b19-medscimonit-25-5801]\]. The *PIWIL1* variant, c.1580G\>A (rs1106042), is a non-synonymous mutation involving a change in amino acid 527 from arginine to lysine. However, this variant has not been previously reported to be associated with disease.

*TAF4B* also called RNA polymerase II and TATA box-binding protein-associated factor (*TAFII105*), shows predominant expression in the testis, while the encoded protein is enriched in mouse gonadal tissue. The *TAF4B* mutation has previously been reported in four brothers and showed phenotypic variability in one brother who was oligospermic and the other three were azoospermic \[[@b20-medscimonit-25-5801]\]. The *TAF4B* variant, c.1815T\>C (rs1677016), is a synonymous mutation that does not change the asparagine at amino acid 605. Again, this variant has not been reported to be associated with disease.

The gene, *SOX10*, encodes a member of the *SRY*-related HMG-box (*SOX*) family of transcription factors that are involved in the regulation of embryonic development and determination of cell fate. The encoded SOX10 protein may act as a transcriptional activator and can activate transcriptional targets of SOX9, explaining at a mechanistic level its ability to direct development in the male testis \[[@b21-medscimonit-25-5801],[@b22-medscimonit-25-5801]\]. The *SOX10* variant, c.927T\>C (rs139884), is a synonymous mutation that does not change the histidine at amino acid 309. There are no reports of this variant being associated with disease, and its functional significance is not yet known.

Clinical interpretation of novel genetic variants is challenging but should gradually become easier with the development of variant databases of healthy controls and locus-specific disease databases. These variant databases could help to identify a set of genes or variants of putative biological functionality of the disease. Genome-wide association studies (GWAS) have now identified more than 2,000 common variants associated with common diseases or related traits (*<http://www.genome.gov/gwastudies>*). The majority of disease risk alleles are common (allele frequency \>5%) and they confer small effect sizes (OR \<1.5). However, these findings might not reflect the full allelic frequency of the spectrum of disease as, for example, lower frequency single-nucleotide polymorphisms (allele frequency \<5%) are not well-described

Based on the hypothesis that low-frequency variants, which are enriched with deleterious, protein-coding mutations, might participate in complex traits, in this study we identified pathogenic rare, low-frequency variants of NOA-associated genes using the Baylor bioinformatic pipeline ([Figure 2](#f2-medscimonit-25-5801){ref-type="fig"}). There were 39 SNV sites that were selected by Baylor's pipeline ([Table 6](#t6-medscimonit-25-5801){ref-type="table"}). The SNV database was constructed using 52 NOA non-negatively associated SNVs and 39 SNVs. Although the data indicated that cases were significantly more likely than controls to contain multiple independent risk SNVs, much larger studies are necessary to accurately characterize the combined effects of multiple independent *loci* on spermatogenic defects.

This was a pilot case-control study of azoospermia. However, the findings from this study highlight the need for future large-scale studies with increased statistical power, as well as genome sequencing of individuals to identify rare variants that are likely to be responsible for a significant proportion of spermatogenic defects. Such studies are becoming technologically feasible but will require improvements in collaboration and funding.

Conclusions
===========

Five genetic variants were shown to be positively correlated with nonobstructive azoospermia (NOA) in the male Han population of northeast China. The single nucleotide variant (SNV) database that was constructed contained NOA non-negatively associated SNVs. The detection of low-frequency variants may be an effective strategy to identify high-risk alleles for NOA.

We thank the patients, research staff, and students of the Genetics Laboratory, Center for Reproductive Medicine.

**Source of support:** Funding was provided by the Science and Technology Department of Jilin Province (20160101048JC)

![Flowchart of the case-control study.](medscimonit-25-5801-g001){#f1-medscimonit-25-5801}

![Flowchart for Baylor's pipeline. 1000G -- 1000 Genomes database; ESP6500 -- ESP6500 database; In house -- in-house data from 4,000 Chinese Han controls.](medscimonit-25-5801-g002){#f2-medscimonit-25-5801}

###### 

Demographic and clinical information of men in the nonobstructive azoospermia (NOA) group and the control group.

  Variables                   NOA group (n=34)                                                                                                       Control group (n=40)
  --------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Information (mean ±SD)                                                                                                                             
   Age                        29.06±4.49[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                         25.08±5.75
   Body mass index (BMI)      26.55±4.59[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                         22.10±2.32
  Physical examination (n)%                                                                                                                          
   Rate of varicocele         (3/34) 8.82%                                                                                                           (0/26)[\#](#tfn2-medscimonit-25-5801){ref-type="table-fn"} 0%
  Semen analysis (mean ±SD)                                                                                                                          
   Concentration (10^6^/ml)   0[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                                  63.53±4.59
   Volume (ml)                3.01±1.41[\#\#](#tfn3-medscimonit-25-5801){ref-type="table-fn"}                                                        3.54±1.08
  Serum hormone (mean ±SD)                                                                                                                           
   FSH (mIU/ml)               15.24±8.17[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                         3.30±2.13
   LH (mIU/ml)                8.06±3.25[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                          4.91±2.46
   PRL (μIU/ml)               259.05±135.37[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}[&](#tfn4-medscimonit-25-5801){ref-type="table-fn"}   426.25±233.16
   E2 (pg/ml)                 36.93±21.96[&&](#tfn5-medscimonit-25-5801){ref-type="table-fn"}                                                        35.64±15.91
   T (nmol/L)                 14.23±9.38[\*](#tfn1-medscimonit-25-5801){ref-type="table-fn"}                                                         18.78±6.92

Compared with the control group, p\<0.05.

n=26;

n=27;

n=32;

n=33.

BMI -- body mass index; FSH -- follicle-stimulating hormone; LH -- luteinizing hormone; PRL -- prolactin; E2 -- estradiol; T -- testosterone; SD -- standard deviation.

###### 

Distribution of the next-generation sequencing (NGS) output data in the gene regions in the nonobstructive azoospermia (NOA) group and the control group.

  Gene region               NOA group (n=34)   Control group (n=40)   Total
  ------------------------- ------------------ ---------------------- --------
  Exonic                    19940              23619                  43559
  Intronic                  53773              62737                  116510
  Regulatory region                                                   17376
   Upstream of 5′ UTR       674                756                    
   Downstream of 3′ UTR     261                314                    
  Upstream and downstream   28                 34                     
   3′ UTR                   2957               3424                   
   5′ UTR                   2010               2354                   
   3′ UTR and 5′ UTR        54                 57                     
  Splicing                  868                983                    
   ncRNA UTR3               96                 93                     
   ncRNA UTR5               24                 35                     
   ncRNA exonic             281                302                    
   ncRNA intronic           808                954                    
   ncRNA splicing           3                  6                      
  Intergenic                749                772                    1521
  Total                     82526              96440                  178966

###### 

Variation classes of next-generation sequencing (NGS) output data in the nonobstructive azoospermia (NOA) group and the control group.

  Type of genetic variation   NOA group (n=82526)                                                   Control group (n=96440)   P-value
  --------------------------- --------------------------------------------------------------------- ------------------------- -------------------------------------------------------
  SNV                                                                                                                         
   Nonsynonymous              \(8388\) 10.16                                                        \(9891\) 10.26            0.522
   Synonymous                 \(10570\) 12.81                                                       \(12508\) 12.97           0.309
   Stop-gain                  \(71\) 0.09                                                           \(79\) 0.08               0.764
   Stop-loss                  \(0\) 0                                                               \(1\) \<0.01              1[\#](#tfn7-medscimonit-25-5801){ref-type="table-fn"}
   Splicing                   \(642\) 0.78                                                          \(768\) 0.80              0.661
   Unknown                    \(43505\) 52.72[\*](#tfn8-medscimonit-25-5801){ref-type="table-fn"}   \(51809\) 53.72           \<0.001
  Indel                                                                                                                       
   Frameshift                 \(208\) 0.25                                                          \(257\) 0.27              0.55
   Non-frameshift             \(482\) 0.58                                                          \(627\) 0.65              0.076
   Stop-loss                  \(28\) 0.03                                                           \(29\) 0.03               0.648
   Unknown                    \(18632\) 22.58[\*](#tfn8-medscimonit-25-5801){ref-type="table-fn"}   \(20471\) 21.23           \<0.001

Fisher's exact test.

Compared with the control group, P\<0.05.

P-value was obtained from logistic regression analysis. SNV -- single nucleotide variant; Indel -- short insertion-deletion.

###### 

List of single nucleotide variants (SNVs) with significant difference in allelic frequencies between the the nonobstructive azoospermia (NOA) group and the control group.

  SNV           Position             Gene       MAF (n) %      P^HWE^                                                                                
  ------------- -------------------- ---------- -------------- -------------- ------- -------------------------------------------------------------- --------------------------------------------------------------
  c.1949C\>T    1p22.1-92457843      BRDT       \(46\) 67.65   \(41\) 51.25   0.043   0.73                                                           0.755
  c.531A\>T     1p34.1-45218895      KIF2C      \(11\) 16.18   \(25\) 31.25   0.033   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.945
  c.1345A\>C    1p34.1-45224998      KIF2C      \(11\) 16.18   \(25\) 31.25   0.033   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.945
  c.1500G\>A    1p34.1-45226084      KIF2C      \(11\) 16.18   \(25\) 31.25   0.033   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.945
  c.719A\>T     1q21.3-154931757     PYGO2      0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.12T\>C      1q24.1-166958601     MAEL       \(9\) 13.24    \(25\) 31.25   0.009   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.505
  c.121T\>G     1q24.1-166958710     MAEL       \(9\) 13.24    \(23\) 28.75   0.022   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.813
  c.1152T\>C    2p13.2-72359518      CYP26B1    \(9\) 13.24    \(3\) 3.75     0.035   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.566T\>C     2p13.2-72361960      CYP26B1    \(9\) 13.24    \(2\) 2.50     0.013   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1199C\>A    2p21-44099433        ABCG8      \(15\) 22.06   \(8\) 10.00    0.044   0.099                                                          1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1764T\>C    4q12-56309992        CLOCK      \(55\) 80.88   \(53\) 66.25   0.046   0.788                                                          0.084
  c.39C\>T      4q35.1-184426387     ING2       \(46\) 67.65   \(38\) 47.50   0.014   0.73                                                           0.536
  c.13286G\>A   5p15.2-13708284      DNAH5      \(4\) 5.88     0              0.028   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.12472C\>T   5p15.2-13719018      DNAH5      \(4\) 5.88     0              0.028   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.537T\>C     5p15.31-7878192      MTRR       \(13\) 19.12   \(6\) 7.50     0.035   0.788                                                          1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1049A\>G    5p15.31-7885959      MTRR       \(13\) 19.12   \(6\) 7.50     0.035   0.788                                                          1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.2006C\>T    5q23.1-118872184     HSD17B4    \(2\) 2.94     \(10\) 12.5    0.034   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1344G\>A    6p21.2-37349033      RNF8       \(43\) 63.24   \(65\) 81.25   0.014   0.239                                                          0.144
  c.261T\>C     6p21.32-32551995     HLA-DRB1   \(26\) 38.24   \(11\) 13.75   0.001   \<0.001                                                        0.014[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.227T\>A     6p21.32-32552029     HLA-DRB1   \(5\) 7.35     \(19\) 23.75   0.007   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.516
  c.171C\>G     6p21.32-32552085     HLA-DRB1   0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   0.124[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.558T\>C     6p21.32-32629847     HLA-DQB1   \(35\) 51.47   \(57\) 71.25   0.013   \<0.001                                                        \<0.001
  c.546T\>C     6p21.32-32629859     HLA-DQB1   \(20\) 29.41   \(41\) 51.25   0.007   \<0.001                                                        \<0.001
  c.485G\>A     6p21.32-32629920     HLA-DQB1   \(15\) 22.06   \(4\) 5.00     0.002   \<0.001                                                        0.075[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.474G\>C     6p21.32-32629931     HLA-DQB1   0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   0.124[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.356T\>A     6p21.32-32632598     HLA-DQB1   \(6\) 8.82     0              0.007   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.266A\>T     6p21.32-32632688     HLA-DQB1   \(16\) 23.53   \(8\) 10.00    0.026   \<0.001                                                        \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.184T\>C     6p21.32-32632770     HLA-DQB1   \(17\) 25.00   \(6\) 7.50     0.003   \<0.001                                                        0.007[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.177G\>A     6p21.32-32632777     HLA-DQB1   \(22\) 32.35   \(12\) 15.00   0.012   \<0.001                                                        0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.30C\>T      6p21.32-32634355     HLA-DQB1   \(7\) 10.29    \(21\) 26.25   0.014   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   \<0.001
  c.47C\>T      6p21.32-33043865     HLA-DPB1   0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.292A\>G     6p21.32-33048640     HLA-DPB1   \(19\) 27.94   \(38\) 47.50   0.015   0.159                                                          0.987
  c.313A\>G     6p21.32-33048661     HLA-DPB1   \(3\) 4.41     \(12\) 15.00   0.033   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.568[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.315G\>A     6p21.32-33048663     HLA-DPB1   \(4\) 5.88     \(18\) 22.50   0.005   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.353
  c.1035C\>T    6p21.33-32008451     CYP21A2    0              \(6\) 7.50     0.021   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   0.183[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.927T\>C     6p22.3-16327615      ATXN1      \(64\) 94.12   \(67\) 83.75   0.049   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.273
  c.633C\>G     8q22.3-103572992     ODF1       \(46\) 67.65   \(36\) 45.00   0.006   \<0.001                                                        \<0.001
  c.642C\>G     8q22.3-103573001     ODF1       \(8\) 11.76    \(2\) 2.50     0.025   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   0.013[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.400A\>G     11p15.4-7110751      RBMXL2     \(60\) 88.24   \(56\) 70.00   0.007   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   \<0.001
  c.1497C\>T    11q21-94335077       PIWIL4     \(6\) 8.82     \(1\) 1.25     0.031   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.933C\>T     12p12.1-23687354     SOX5       \(11\) 16.18   \(4\) 5.00     0.025   0.562[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.2265A\>G    12q14.2-63954304     DPY19L2    \(10\) 14.71   \(23\) 28.75   0.041   0.123[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     0.813
  c.1580G\>A    12q24.33-130841638   PIWIL1     \(11\) 16.18   \(4\) 5.00     0.025   0.562[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.4340G\>C    14q11.2-20850156     TEP1       0              \(6\) 7.50     0.021   0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     0.183[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1860G\>T    14q11.2-20863677     TEP1       \(4\) 5.88     \(16\) 20.00   0.012   0.089[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     0.553
  c.1384A\>G    15q24.1-75012985     CYP1A1     \(26\) 38.24   \(17\) 21.25   0.023   0.028                                                          0.446
  c.719C\>T     17p13.3-2995572      OR1D2      0              \(5\) 6.25     0.036   \<0.001                                                        c.719C\>T
  c.297A\>G     17p13.3-2995994      OR1D2      0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.81C\>T      17q23.3-61562309     ACE        \(40\) 58.82   \(63\) 78.75   0.009   0.588                                                          0.259
  c.471A\>G     17q23.3-61564052     ACE        \(40\) 58.82   \(63\) 78.75   0.009   0.588                                                          0.259
  c.606G\>A     17q23.3-61566031     ACE        \(40\) 58.82   \(63\) 78.75   0.009   0.588                                                          0.259
  c.1665T\>C    17q23.3-61573761     ACE        \(35\) 51.47   \(61\) 76.25   0.002   0.168                                                          0.553
  c.663C\>T     18q11.2-23854692     TAF4B      \(2\) 2.94     \(10\) 12.5    0.034   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1476G\>A    18q11.2-23866349     TAF4B      \(2\) 2.94     \(10\) 12.5    0.034   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1815T\>C    18q11.2-23873463     TAF4B      \(62\) 91.18   \(59\) 73.75   0.006   0.214[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}     0.537
  c.24A\>G      19p13.3-917526       KISS1R     \(4\) 5.88     \(13\) 16.25   0.049   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.273
  c.303G\>A     19p13.3-2249634      AMH        \(16\) 23.53   \(8\) 10.00    0.026   0.287                                                          1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.526C\>T     19q13.32-45412079    APOE       \(7\) 10.29    \(2\) 2.50     0.048   0.29[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}      1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.585G\>C     20p12.3-5283256      PROKR2     \(41\) 60.29   \(61\) 76.25   0.037   0.33                                                           0.516
  c.465C\>T     20p12.3-5283376      PROKR2     \(29\) 42.65   \(49\) 61.25   0.024   0.567                                                          0.184
  c.2037C\>T    20q13.2-50406985     SALL4      0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.1056G\>A    20q13.2-50407966     SALL4      0              \(5\) 6.25     0.036   \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.927T\>C     22q13.1-38369976     SOX10      \(60\) 88.24   \(57\) 71.25   0.011   1[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}         0.313
  c.114C\>T     Xp21.2-30327367      NR0B1      \(19\) 27.94   \(10\) 12.5    0.018   \<0.001                                                        \<0.001[\*](#tfn10-medscimonit-25-5801){ref-type="table-fn"}
  c.576G\>A     Xq26.2-132161673     USP26      \(30\) 44.12   \(20\) 25.00   0.014   \<0.001                                                        \<0.001

Fisher's exact test.

MAF -- minor allele frequency.

###### 

Analysis of the correlation between single nucleotide variant (SNV) alleles and nonobstructive azoospermia (NOA) identified using the Human Gene Mutation Database (HGMD).

  SNV                  SNP ID       HGMD   Unadjusted correlation   Adjusted correlation                           
  -------------------- ------------ ------ ------------------------ ---------------------- ----------------------- -------
  BRDT c.1949C\>T      rs10747493   --     1.989 (1.017--3.891)     0.045                  1.773 (0.859--3.660)    0.121
  KIF2C c.531A\>T      rs3795713    --     0.425 (0.191--0.945)     0.036                  0.291 (0.114--0.742)    0.01
  KIF2C c.1345A\>C     rs4342887    --     0.425 (0.191--0.945)     0.036                  0.291 (0.114--0.742)    0.01
  KIF2C c.1500G\>A     rs1140279    --     0.425 (0.191--0.945)     0.036                  0.291 (0.114--0.742)    0.01
  MAEL c.12T\>C        rs2296837    --     0.336 (0.144--0.782)     0.011                  0.316 (0.126--0.796)    0.015
  MAEL c.121T\>G       rs11578336   --     0.378 (0.161--0.886)     0.025                  0.345 (0.136--0.878)    0.025
  CYP26B1 c.1152T\>C   rs12478279   --     3.915 (1.015--15.102)    0.048                  2.718 (0.643--11.488)   0.174
  CYP26B1 c.566T\>C    rs2241057    --     5.949 (1.239--28.568)    0.026                  3.779 (0.732--19.494)   0.112
  ABCG8 c.1199C\>A     rs4148217    DFP    2.547 (1.007--6.446)     0.048                  2.020 (0.746--5.472)    0.167
  CLOCK c.1764T\>C     rs3736544    --     2.155 (1.006--4.616)     0.048                  1.818 (0.795--4.153)    0.156
  ING2 c.39C\>T        rs8872       --     2.311 (1.181--4.522)     0.014                  2.031 (0.983--4.194)    0.056
  MTRR c.537T\>C       rs161870     --     2.915 (1.042--8.152)     0.041                  3.686 (1.228--11.066)   0.02
  MTRR c.1049A\>G      rs162036     --     2.915 (1.042--8.152)     0.041                  3.686 (1.228--11.066)   0.02
  HSD17B4 c.2006C\>T   rs28943592   --     0.212 (0.045--1.004)     0.051                  0.225 (0.043--1.170)    0.076
  RNF8 c.1344G\>A      rs2284922    --     0.397 (0.188--0.838)     0.015                  0.467 (0.208--1.049)    0.065
  HLA-DRB1 c.227T\>A   rs17884945   --     0.255 (0.09--0.725)      0.01                   0.254 (0.079--0.818)    0.022
  HLA-DPB1 c.292A\>G   rs1042140    --     0.429 (0.215--0.853)     0.016                  0.431 (0.203--0.914)    0.028
  HLA-DPB1 c.313A\>G   rs1042151    --     0.262 (0.071--0.969)     0.045                  0.198 (0.045--0.866)    0.031
  HLA-DPB1 c.315G\>A   rs1042153    --     0.215 (0.069--0.672)     0.008                  0.181 (0.050--0.651)    0.009
  ATXN1 c.927T\>C      rs179990     --     3.104 (0.962--10.021)    0.058                  2.859 (0.784--10.423)   0.112
  PIWIL4 c.1497C\>T    rs624184     --     7.645 (0.897--65.172)    0.063                  7.595 (0.815--70.789)   0.075
  SOX5 c.933C\>T       rs61756181   --     3.667 (1.110--12.111)    0.033                  3.145 (0.895--11.049)   0.074
  DPY19L2 c.2265A\>G   rs1054891    --     0.427 (0.187--0.977)     0.044                  0.414 (0.164--1.048)    0.063
  PIWIL1 c.1580G\>A    rs1106042    --     3.667 (1.110--12.111)    0.033                  4.737 (1.314--17.072)   0.017
  TEP1 c.1860G\>T      rs2228036    --     0.25 (0.079--0.789)      0.018                  0.471 (0.142--1.558)    0.217
  ACE c.81C\>T         rs4316       --     0.385 (0.187--0.793)     0.01                   0.351 (0.160--0.767)    0.009
  ACE c.471A\>G        rs4331       --     0.385 (0.187--0.793)     0.01                   0.351 (0.160--0.767)    0.009
  ACE c.606G\>A        rs4343       --     0.385 (0.187--0.793)     0.01                   0.351 (0.160--0.767)    0.009
  ACE c.1665T\>C       rs4362       --     0.330 (0.164--0.666)     0.002                  0.283 (0.131--0.612)    0.001
  TAF4B c.663C\>T      rs17224558   --     0.212 (0.045--1.004)     0.051                  0.185 (0.032--1.059)    0.058
  TAF4B c.1476G\>A     rs3744961    --     0.212 (0.045--1.004)     0.051                  0.185 (0.032--1.059)    0.058
  TAF4B c.1815T\>C     rs1677016    --     3.678 (1.388--9.749)     0.009                  3.599 (1.255--10.327)   0.017
  KISS1R c.24A\>G      rs10407968   --     0.322 (0.100--1.040)     0.058                  0.277 (0.074--1.038)    0.057
  AMH c.303G\>A        rs61736575   --     2.769 (1.103--6.953)     0.03                   2.449 (0.922--6.506)    0.072
  APOE c.526C\>T       rs7412       DFP    4.475 (0.897--22.318)    0.068                  4.860 (0.899--26.276)   0.066
  PROKR2 c.585G\>C     rs3746682    --     0.473 (0.233--0.960)     0.038                  0.556 (0.258--1.197)    0.133
  PROKR2 c.465C\>T     rs3746684    --     0.470 (0.244--0.909)     0.025                  0.515 (0.252--1.051)    0.068
  SOX10 c.927T\>C      rs139884     --     3.026 (1.252--7.314)     0.014                  3.192 (1.220--8.353)    0.018

P\<0.05 was statistically significant. "--" -- no visible record after query. DFP -- disease-associated polymorphisms with additional supporting functional evidence; SNP -- single nucleotide polymorphism; ID -- identity; HGMD -- Human Gene Mutation Database; OR -- odds ratio; CI -- confidence interval.

###### 

Candidate single nucleotide variants (SNVs) selected by Baylor's pipeline method with the allelic frequency represented as 0 in the control group.

  SNV           Gene       HGMD   MAF (database)   SIFT       PolyPhen2   GERP++                            
  ------------- ---------- ------ ---------------- ---------- ----------- -------- ---- ------- ---- ------ -----
  c.907G\>A     MTHFR      --     --               0.000077   0.0016644   0.01     D    0.999   PD   4.17   Con
  c.1495C\>T    PLOD1      --     0.0009           0.000077   0.0019973   0        D    0.997   PD   4.62   Con
  c.1160A\>C    LHX4       --     0.0009           --         --          0        D    1       PD   5.79   Con
  c.319C\>G     CYP1B1     DM     0.0005           --         0.0013316   0        D    1       PD   2.73   Con
  c.613G\>A     ABCG8      --     --               0.000077   --          0.01     D    1       PD   3.28   Con
  c.289C\>T     M1AP       --     0.0005           --         --          0        D    1       PD   5.77   Con
  c.1165C\>T    HS6ST1     --     --               0.000081   --          --       --   0.912   Pd   2.21   Con
  c.2012C\>T    IL17RD     --     0.0009           --         0.0023302   0        D    1       PD   5.79   Con
  c.1552C\>T    MORC1      --     --               --         0.0026631   0.02     D    0.967   PD   3.82   Con
  c.2047C\>T    DNAH5      --     0.0023           --         0.0049933   0.01     D    0.924   Pd   4.68   Con
  c.965C\>T     HSD17B4    --     --               0.000154   \-          0.02     D    0.999   PD   5.49   Con
  c.1216C\>T    CYP21A2    DM     --               --         0.0003329   0        D    1       PD   4.55   Con
  c.164G\>T     HLA-DQB1   --     --               --         0.0006658   0.01     D    0.976   PD   2.05   Con
  c.177C\>A     BRD2       --     0.0032           0.002076   0.0006658   --       --   --      --   4.5    Con
  c.314C\>T     BRD2       --     --               0.000308   --          0.03     D    0.999   PD   5.16   Con
  c.621C\>T     BRD2       --     0.0023           --         0.0033289   --       --   --      --   1.87   Non
  c.136G\>C     HLA-DPB1   --     0.0005           --         0.0003329   0        D    0.946   Pd   3.93   Con
  c.874C\>T     IGF2R      --     0.0005           --         --          0.01     D    1       PD   3.9    Con
  c.3944G\>A    IGF2R      --     0.0027           --         0.0046605   0.02     D    0.989   PD   5.48   Con
  c.10411G\>A   DNAH11     --     0.0046           --         0.0009987   0.03     D    0.985   PD   4.94   Con
  c.458G\>A     FKBP6      --     --               0.000084   --          0.01     D    0.998   PD   5.46   Con
  c.3289C\>T    CFTR       --     0.0005           --         --          0        D    1       PD   5.69   Con
  c.1002C\>A    EPHX2      --     0.0005           --         0.0003329   0.02     D    0.962   PD   4.64   Con
  c.97G\>A      ARID5B     --     0.0005           --         0.0013316   0.03     D    0.964   PD   6.03   Con
  c.1366G\>A    POLR3A     --     0.0005           --         --          --       --   0.917   Pd   5.9    Con
  c.2558A\>G    NLRP14     --     0.0005           --         0.0003329   0.01     D    1       PD   3.06   Con
  c.34C\>T      H1FNT      --     0.0046           --         0.0049933   0.01     D    0.968   PD   1.95   Non
  c.5306C\>T    TEP1       --     --               --         0.0003329   0        D    0.803   Pd   3.85   Con
  c.1093A\>G    TEP1       --     --               --         0.0006658   0.01     D    0.64    Pd   4.54   Con
  c.475C\>T     CYP19A1    --     0.0009           --         --          0        D    1       PD   5.85   Con
  c.1475C\>G    CYP1A1     --     0.0014           --         0.0016644   0.02     D    0.878   Pd   4.68   Con
  c.2890C\>T    POLG       DM     0.0018           --         0.0023302   0        D    1       PD   5.24   Con
  c.266C\>T     12-Sep     DM     0.03             --         --          0        D    1       PD   4.73   Con
  c.397C\>T     PRM2       --     0.0005           0.000083   --          0.04     D    0.978   PD   2.76   Con
  c.1699A\>G    ALOX15     --     0.0014           --         0.0003329   0.03     D    0.873   Pd   4.33   Con
  c.607G\>A     KLHL10     --     0.0005           --         0.0013316   --       --   0.992   PD   5.73   Con
  c.1141G\>A    XRCC1      --     --               --         0.0003329   0.01     D    1       PD   4.11   Con
  c.3060T\>C    SON        --     0.0009           --         0.0006658   --       --   --      --   1.09   Non
  c.528C\>A     AR         --     --               --         0.0016644   0.01     D    0.999   PD   5.21   Con

SNV -- single nucleotide variant; HGMD -- Human Gene Mutation Database; MAF -- minor allele frequency; ESP, NHLBI GO Exome Sequencing Project; SIFT -- sorting intolerant from tolerant, using sequence homology gene sequencing; Polyphen2, Polymorphism Phenotyping version 2; GERP -- Genomic Evolutionary Rate Profiling; Pre -- prediction; DM -- disease-causing mutation; D -- damaging; PD -- probably damaging; Pd -- possibly damaging; Con -- conserved; Non -- nonconserved; het -- heterozygote; hom, homozygote.
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